Drugs / AUR107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05865002 | Sep 2023 → Jan 2027 expected | refractory malignant neoplasm | Aurigene Discovery Technologies Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUR107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05865002 ↗ |
| Route | Oral | “oral AUR107” NCT05865002 ↗ |